Nomenclature for human CYP2D6 alleles

被引:382
|
作者
Daly, AK
Brockmoller, J
Broly, F
Eichelbaum, M
Evans, WE
Gonzalez, FJ
Huang, JD
Idle, JR
IngelmanSundberg, M
Ishizaki, T
JacqzAigrain, E
Meyer, UA
Nebert, DW
Steen, VM
Wolf, CR
Zanger, UM
机构
[1] HUMBOLDT UNIV BERLIN, INST KLIN PHARMAKOL, KLINIKUM CHARITE, D-10098 BERLIN, GERMANY
[2] CTR HOSP REG & UNIV LILLE, HOP CALMETTE, LAB BIOCHIM & BIOL MOL, F-59037 LILLE, FRANCE
[3] DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, D-70376 STUTTGART, GERMANY
[4] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA
[5] NCI, MOLEC CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA
[6] NATL CHENG KUNG UNIV, DEPT PHARMACOL, TAINAN 70101, TAIWAN
[7] KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN
[8] INT MED CTR JAPAN, RES INST, DEPT CLIN PHARMACOL, SHINJUKU KU, TOKYO 162, JAPAN
[9] HOP ROBERT DEBRE, INSERM U120, F-75019 PARIS, FRANCE
[10] HOP ROBERT DEBRE, DEPT CLIN PHARMACOL, F-75019 PARIS, FRANCE
[11] UNIV BASEL, BIOCTR, ABT PHARMAKOL, CH-4056 BASEL, SWITZERLAND
[12] UNIV CINCINNATI, MED CTR, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA
[13] HAUKELAND HOSP, CTR MOL MED, DR EINAR MARTENS RES GRP BIOL PSYCHIAT, N-5021 BERGEN, NORWAY
[14] UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
allele nomenclature; CYP2D6;
D O I
10.1097/00008571-199606000-00001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To standardize CYP2D6 allele nomenclature, and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described, Based on recommendations for human genome nomenclature, we propose that alleles be designated by CYP2D6 followed by an asterisk and a combination of roman letters and arabic numerals distinct for each allele with the number specifying the key mutation and, where appropriate, a letter specifying additional mutations, Criteria for classification as a separate allele and protein nomenclature are also presented.
引用
收藏
页码:193 / 201
页数:9
相关论文
共 50 条
  • [1] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [2] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [3] CYP2D6: novel genomic structures and alleles
    Kramer, Whitney E.
    Walker, Denise L.
    O'Kane, Dennis J.
    Mrazek, David A.
    Fisher, Pamela K.
    Dukek, Brian A.
    Bruflat, Jamie K.
    Black, John L.
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (10): : 813 - 828
  • [4] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [5] FREQUENCY OF HUMAN CYP2D6 MUTANT ALLELES IN A NORMAL CHINESE POPULATION
    LEE, EJD
    JEYASEELAN, K
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) : 605 - 607
  • [6] Effects of CYP2D6*10 and CYP2D6*5 alleles on the pharmacokinetics of carvedilol in healthy Koreans.
    Kang, Byung-Sung
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E301 - E301
  • [7] Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population
    Ishiguro, A
    Kubota, T
    Sasaki, H
    Yamada, Y
    Iga, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 414 - U3
  • [8] Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients:: therapeutic consequences?
    Haffen, E
    Vandel, P
    Paintaud, G
    Broly, F
    Vandel, S
    Bonin, B
    Bizouard, P
    Sechter, D
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 55 (11-12) : 877 - 879
  • [9] Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?
    E. Haffen
    P. Vandel
    G. Paintaud
    F. Broly
    S. Vandel
    B. Bonin
    P. Bizouard
    D. Sechter
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 2000, 55 : 877 - 879
  • [10] Polymorphism of CYP2D6 alleles in Parkinson's disease
    Lisak, M.
    Stefanovic, M.
    Bedekovic, M. Roje
    Trkanjec, Z.
    Demarin, V.
    MOVEMENT DISORDERS, 2009, 24 : S145 - S145